Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Apr;80(1-2):51–58. doi: 10.1038/sj.bjc.6690320

DCC expression is related to mucinous differentiation but not changes in expression of p21WAF1/Cip1 and p27Kip1, apoptosis, cell proliferation and human papillomavirus infection in uterine cervical adenocarcinomas

M Saegusa 1, I Okayasu 1
PMCID: PMC2363019  PMID: 10389977

Abstract

To clarify possible roles of DCC expression in tumour differentiation and cell kinetics, we immunohistochemically investigated 80 uterine cervical adenocarcinomas (C-ACs), including 31 mucinous (M) and 31 endometrioid (E) lesions, and 18 adenocarcinomas in situ (AIS), along with 39 normal cervical samples. The results were compared with findings for p21WAF1/Cip1 and p27Kip1 expression, apoptosis, cell proliferation and human papillomavirus (HPV) infection. Nine C-AC cases were also examined using a combination of the reverse transcription-polymerase chain reaction and Southern blot hybridization, as well as Western blot assays. Significantly decreased DCC scores were observed in E-ACs but not M-ACs, as compared to normal cervical glandular epithelia and AIS. Average p21WAF1/Cip1 and p27Kip1 scores were significantly higher in E-ACs than M-ACs, in line with high apoptotic, mitotic and Ki-67 labelling indices. A concordance of the results for DCC and p21WAF1/Cip1 expression between mRNA- and protein-based assays was also noted. Change of DCC expression, however, was not related to any of the cell kinetic markers or clinicopathological features in ACs of either type. There was also no association with the HPV status, although infection was significantly linked with high values for cell kinetics. These results suggest that DCC expression in C-ACs is closely associated with mucinous differentiation. © 1999 Cancer Research Campaign

Keywords: uterine cervix, adenocarcinoma, DCC, p21WAF1/Cip1, p27Kip1, apoptosis

Full Text

The Full Text of this article is available as a PDF (406.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Coates P. J., d'Ardenne A. J., Khan G., Kangro H. O., Slavin G. Simplified procedures for applying the polymerase chain reaction to routinely fixed paraffin wax sections. J Clin Pathol. 1991 Feb;44(2):115–118. doi: 10.1136/jcp.44.2.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Enomoto T., Fujita M., Cheng C., Nakashima R., Ozaki M., Inoue M., Nomura T. Loss of expression and loss of heterozygosity in the DCC gene in neoplasms of the human female reproductive tract. Br J Cancer. 1995 Mar;71(3):462–467. doi: 10.1038/bjc.1995.94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fearon E. R., Cho K. R., Nigro J. M., Kern S. E., Simons J. W., Ruppert J. M., Hamilton S. R., Preisinger A. C., Thomas G., Kinzler K. W. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science. 1990 Jan 5;247(4938):49–56. doi: 10.1126/science.2294591. [DOI] [PubMed] [Google Scholar]
  4. Gao X., Honn K. V., Grignon D., Sakr W., Chen Y. Q. Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res. 1993 Jun 15;53(12):2723–2727. [PubMed] [Google Scholar]
  5. Gima T., Kato H., Honda T., Imamura T., Sasazuki T., Wake N. DCC gene alteration in human endometrial carcinomas. Int J Cancer. 1994 May 15;57(4):480–485. doi: 10.1002/ijc.2910570407. [DOI] [PubMed] [Google Scholar]
  6. Ginsberg D., Mechta F., Yaniv M., Oren M. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):9979–9983. doi: 10.1073/pnas.88.22.9979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Goi T., Yamaguchi A., Nakagawara G., Urano T., Shiku H., Furukawa K. Reduced expression of deleted colorectal carcinoma (DCC) protein in established colon cancers. Br J Cancer. 1998;77(3):466–471. doi: 10.1038/bjc.1998.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hannon G. J., Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 1994 Sep 15;371(6494):257–261. doi: 10.1038/371257a0. [DOI] [PubMed] [Google Scholar]
  9. Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993 Nov 19;75(4):805–816. doi: 10.1016/0092-8674(93)90499-g. [DOI] [PubMed] [Google Scholar]
  10. Hedrick L., Cho K. R., Fearon E. R., Wu T. C., Kinzler K. W., Vogelstein B. The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev. 1994 May 15;8(10):1174–1183. doi: 10.1101/gad.8.10.1174. [DOI] [PubMed] [Google Scholar]
  11. Huang Y., Boynton R. F., Blount P. L., Silverstein R. J., Yin J., Tong Y., McDaniel T. K., Newkirk C., Resau J. H., Sridhara R. Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res. 1992 Dec 1;52(23):6525–6530. [PubMed] [Google Scholar]
  12. Jordan R. C., Bradley G., Slingerland J. Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am J Pathol. 1998 Feb;152(2):585–590. [PMC free article] [PubMed] [Google Scholar]
  13. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., 3rd, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994 Apr 15;264(5157):436–440. doi: 10.1126/science.8153634. [DOI] [PubMed] [Google Scholar]
  14. Kerr J. F., Winterford C. M., Harmon B. V. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994 Apr 15;73(8):2013–2026. doi: 10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  15. Kikuchi-Yanoshita R., Konishi M., Fukunari H., Tanaka K., Miyaki M. Loss of expression of the DCC gene during progression of colorectal carcinomas in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res. 1992 Jul 1;52(13):3801–3803. [PubMed] [Google Scholar]
  16. Klingelhutz A. J., Hedrick L., Cho K. R., McDougall J. K. The DCC gene suppresses the malignant phenotype of transformed human epithelial cells. Oncogene. 1995 Apr 20;10(8):1581–1586. [PubMed] [Google Scholar]
  17. Kong X. T., Choi S. H., Inoue A., Xu F., Chen T., Takita J., Yokota J., Bessho F., Yanagisawa M., Hanada R. Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma. Cancer Res. 1997 Sep 1;57(17):3772–3778. [PubMed] [Google Scholar]
  18. Koshida Y., Saegusa M., Okayasu I. Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br J Cancer. 1997;75(3):367–373. doi: 10.1038/bjc.1997.60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mercer W. E., Shields M. T., Lin D., Appella E., Ullrich S. J. Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1958–1962. doi: 10.1073/pnas.88.5.1958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nadal A., Jares P., Cazorla M., Fernández P. L., Sanjuan X., Hernandez L., Pinyol M., Aldea M., Mallofré C., Muntané J. p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. J Pathol. 1997 Oct;183(2):156–163. doi: 10.1002/(SICI)1096-9896(199710)183:2<156::AID-PATH908>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  21. Narayanan R., Lawlor K. G., Schaapveld R. Q., Cho K. R., Vogelstein B., Bui-Vinh Tran P., Osborne M. P., Telang N. T. Antisense RNA to the putative tumor-suppressor gene DCC transforms Rat-1 fibroblasts. Oncogene. 1992 Mar;7(3):553–561. [PubMed] [Google Scholar]
  22. Nobori T., Miura K., Wu D. J., Lois A., Takabayashi K., Carson D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994 Apr 21;368(6473):753–756. doi: 10.1038/368753a0. [DOI] [PubMed] [Google Scholar]
  23. Park D. J., Wilczynski S. P., Paquette R. L., Miller C. W., Koeffler H. P. p53 mutations in HPV-negative cervical carcinoma. Oncogene. 1994 Jan;9(1):205–210. [PubMed] [Google Scholar]
  24. Polyak K., Kato J. Y., Solomon M. J., Sherr C. J., Massague J., Roberts J. M., Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994 Jan;8(1):9–22. doi: 10.1101/gad.8.1.9. [DOI] [PubMed] [Google Scholar]
  25. Reale M. A., Hu G., Zafar A. I., Getzenberg R. H., Levine S. M., Fearon E. R. Expression and alternative splicing of the deleted in colorectal cancer (DCC) gene in normal and malignant tissues. Cancer Res. 1994 Aug 15;54(16):4493–4501. [PubMed] [Google Scholar]
  26. Saegusa M., Kamata Y., Isono M., Okayasu I. Bcl-2 expression is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endometrial carcinomas. J Pathol. 1996 Nov;180(3):275–282. doi: 10.1002/(SICI)1096-9896(199611)180:3<275::AID-PATH660>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  27. Saegusa M., Takano Y., Hashimura M., Shoji Y., Okayasu I. The possible role of bcl-2 expression in the progression of tumors of the uterine cervix. Cancer. 1995 Dec 1;76(11):2297–2303. doi: 10.1002/1097-0142(19951201)76:11<2297::aid-cncr2820761118>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  28. Serrano M., Hannon G. J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993 Dec 16;366(6456):704–707. doi: 10.1038/366704a0. [DOI] [PubMed] [Google Scholar]
  29. Sgambato A., Zhang Y. J., Arber N., Hibshoosh H., Doki Y., Ciaparrone M., Santella R. M., Cittadini A., Weinstein I. B. Deregulated expression of p27(Kip1) in human breast cancers. Clin Cancer Res. 1997 Oct;3(10):1879–1887. [PubMed] [Google Scholar]
  30. Toh Y., Kuwano H., Tanaka S., Baba K., Matsuda H., Sugimachi K., Mori R. Detection of human papillomavirus DNA in esophageal carcinoma in Japan by polymerase chain reaction. Cancer. 1992 Nov 1;70(9):2234–2238. doi: 10.1002/1097-0142(19921101)70:9<2234::aid-cncr2820700903>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  31. Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994 Jul 15;78(1):67–74. doi: 10.1016/0092-8674(94)90573-8. [DOI] [PubMed] [Google Scholar]
  32. Uchino S., Tsuda H., Noguchi M., Yokota J., Terada M., Saito T., Kobayashi M., Sugimura T., Hirohashi S. Frequent loss of heterozygosity at the DCC locus in gastric cancer. Cancer Res. 1992 Jun 1;52(11):3099–3102. [PubMed] [Google Scholar]
  33. Werness B. A., Levine A. J., Howley P. M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990 Apr 6;248(4951):76–79. doi: 10.1126/science.2157286. [DOI] [PubMed] [Google Scholar]
  34. Yasui W., Akama Y., Kuniyasu H., Yokozaki H., Semba S., Shimamoto F., Tahara E. Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol. 1996 Oct;180(2):122–128. doi: 10.1002/(SICI)1096-9896(199610)180:2<122::AID-PATH647>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  35. Yasui W., Kudo Y., Semba S., Yokozaki H., Tahara E. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res. 1997 Jul;88(7):625–629. doi: 10.1111/j.1349-7006.1997.tb00428.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993 Nov 19;75(4):817–825. doi: 10.1016/0092-8674(93)90500-p. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES